Nieuwe behoeften vragen om nieuwe voorzieningen

Literatuur

Bloedoverdraagbare infecties

Biesert L, et al. Solvent/Detergent Treatment of Human Plasma – A Very Robust Method for Virus Inactivation. Validated Virus Safety of Octaplas®, Vox Sang 1998; 74, Suppl. 1: 207-212

Rollag H, et al. Viral Safety of Blood Derivatives by Immune Neutralization. Vox Sang. 1998;74 Suppl 1:213-7.

Solheim B, et al. Viral safety of solvent / detergent-treated plasma. Transfusion.  2000 Jan; 40(1):84-90.

Neisser-Svae A. et al. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG ® Vox Sang. 2009 Oct;97(3):226-33.

Heger A. et al. Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing – results from animal bioassay studies. Vox Sang. 2012 May;102(4):294-301

Heger A. Biochemical quality of the pharmaceutically licensed plasma OctaplasLG® after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang. 2009 Oct;97(3):219-25

Hellstern P. et al. The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma. Transfus Med Hemother 2011;38:65–70

Samenstelling

Heger A, et al. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas®) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfusion and Apheresis Science 35 (2006) 223–233

Freeman J.W. A randomized trial of Solvent/Detergent-treated and Standard Fresh Frozen Plasma in the Treatment of the Coagulopathy seen during Orthotopic Liver Transplantation. Vox Sang. 1998;74 Suppl 1:225-9.

Hellstern P. Solvent/detergent-treated plasma: composition, efficacy and safety. Curr Opin Hematol 11:346–350.

Lawrie A.S. et al. The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sang. 2010 Oct;99(3):232-8.

TRALI en HLA antistoffen

Sinnott P. et al. Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas®). Eur J Immunogenet. 2004 Dec;31(6):271-4.

Sachs U.J.H. et al. White blood cell–reactive antibodies are undetectable in solvent/detergent plasma. Transfusion. 2005 Oct;45(10):1628-31.

Sachs U.J.H. Pathophysiology of TRALI: current concepts. Intensive Care Med (2007) 33[Suppl 1]:S3–S11

Wallis J.P. Transfusion-related acute lung injury (TRALI): presentation, epidemiology and treatment. Intensive Care Med (2007) 33[Suppl 1]:S12–S16

Sachs U.J.H. Pathogenesis of transfusion-related acute lung injury and how to avoid this serious adverse reaction of transfusion. Transfusion and Apheresis Science 37 (2007) 273-282

Chapman C. E. et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009 Mar;49(3):440-52
 

Hemovigilantie/farmacovigilantie

Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med (2007) 33[Suppl 1]:S17–S21

Baudoux et al. Hemovigilance: clinical tolerance of solvent-detergent treated plasma. Vox Sang. 1998;74 Suppl 1:237-9.

Wiersum-Ossleton J.C. et al. Male-only fresh-frozen plasma for transfusion-related acute lung injury prevention: before-and-after comparative cohort study. Transfusion. 2011 Jun;51(6):1278-83.

Torsvik Steinsvåg C. et al. Eight years with haemovigilance in Norway. What have we learnt? Transfus and Apher Sci 49 (2013) 548–552

Chapman C. E. et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009 Mar;49(3):440-52

TTP

Scully M. et al. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang. 2007 Aug;93(2):154-8.

Kentouche K. et al. Remission of thrombotic thrombocytopenic purpura in a patient with
compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma
.
Acta Peadiatr 2002; 91: 1056-1059.

Harrison C.N. et al. Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol. 1996 Sep;94(4):756-8.

Evans G. et al. Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haematol. 1999 Apr;21(2):119-23.

Efficacy and Safety Profile of Solvent/Detergent

Edel E. et al. Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience. Transfus Med Hemother 2010;37:13–19

Heger A. Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas®) and in the universally applicable plasma (Uniplas) in development. Vox Sang. 2007 Apr;92(3):206-12.

Coagulopathy

Freeman J.W. A randomized trial of Solvent/Detergent-treated and Standard Fresh Frozen Plasma in the Treatment of the Coagulopathy seen during Orthotopic Liver Transplantation. Vox Sang. 1998;74 Suppl 1:225-9.

Williamson L.M. A randomized trial of Solvent/Detergent-treated and Standard Fresh Frozen Plasma in the Coagulopathy of liver disease and liver transplantation. Transfusion. 1999 Nov-Dec;39(11-12):1227-34.

Inbal A. et al. Evaluation of Solvent/Detergent-treated Plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis. 1993 Aug;4(4):599-604.

Salooja N. Severe factor V deficiency and neonatal intracranial haemorrhage: a case report. Haemophilia (2000), 6, 44-46

De Jonge J. et al. Fibrinolysis During Liver Transplantation Is Enhanced by Using Solvent/Detergent Virus-Inactivated Plasma (ESDEP®). Anesth Analg 2002;94:1127–31

Haugaa H et al. Low Incidence of Hyperfibrinolysis and Thromboembolism in 195 Primary Liver Transplantations Transfused with Solvent/Detergent Treated Plasma. Clin Med Res. 2014 Jan 10. [Epub ahead of print]


Ontdooien en ontdooid bewaren

Buchta C. et al. Stability of coagulation factors in thawed, solvent/detergent treated plasma during storage at 4 °C for 6 days. Vox Sang. (2004) 87, 182–186

Heger A. et al. Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing. Transfus Apher Sci. 2005 Nov;33(3):257-67. Epub 2005 Oct 3.

Keller M.K. et al. Clotting factor activity in thawed Octaplas® LG during storage at 2–6 °C for 6 days from a quality assurance point of view. Transfusion and Apheresis Science 46 (2012) 129–136

Keller M.K. et al. Thawed solvent/detergent-treated plasma: too precious to be wasted after 6 hours? Blood Transfus 2012; 10: 360-7

Beck K.H. et al. Thawing of Fresh Frozen Plasma and Virus-Inactivated Plasma – Suitability of Microwave Oven Infusion Therapy and Transfusion Medicine 01/2002; 29(6):313-317

Heger A. et al. A biochemical quality study of a pharmaceutically licenced coagulation active plasma (Octaplas®) thawed by the SAHARA-III dry tempering system compared to the regular use of a water bath Vox Sang. 2008 Jan;94(1):48-55


Gebruik in kinderen

Chekrizova V. Solvent–detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfusion Medicine, 2006, 16, 85–91

Haller W. et al. Successful Isolated Liver Transplantation in a Child with Atypical Hemolytic Uremic Syndrome and a Mutation in Complement Factor H. American Journal of Transplantation 2010; 10: 2142–2147

Salooja N. Severe factor V deficiency and neonatal intracranial haemorrhage: a case report. Haemophilia (2000), 6, 44-46

Witt V. et al. Total plasma exchange using Octaplas; safety and coagulation parameters in children (abstract). Journal of Clinical Apheresis 28 (2013), 129

 

Laatst bewerkt op: 15 september 2014